Robert Sims, Ph.D.


Robert Sims

Robert focuses on drug discovery and development opportunities at Third Rock. He joins Third Rock from Constellation, where he was a founding scientist and most recently senior vice president of research. With nearly 20 years of experience in chromatin biology and transcription, Robert helped establish Constellation’s integrated epigenetics platform. Robert led the discovery and translational efforts for CPI-0610, a potent and selective inhibitor of BET proteins. His team’s notable work, along with others in the field, includes the discovery that BET inhibition silences the expression of the MYC oncogene. Robert has authored more than 30 scientific publications in top-tier journals, including Science, Nature, and Cell.

Year Joined
  • 2019
  • B.S., Microbiology, University of Texas at Austin
  • Ph.D., Cellular and Molecular Biology, University of Texas at Austin
  • East Coast